Antibiotic Resistance Threats in the United States, 2013 report

More documents

Recommendations

Info

THREAT LEVEL SERIOUS MICROORGANISMS WITH A THREAT LEVEL OF SERIOUS Multidrug-resistant Acinetobacter Drug-resistant Campylobacter Fluconazole-resistant Candida (a fungus) Extended spectrum β-lactamase producing Enterobacteriaceae (ESBLs) Vancomycin-resistant Enterococcus (VRE) Multidrug-resistant Pseudomonas aeruginosa Drug-resistant non-typhoidal Salmonella Drug-resistant Salmonella Typhi Drug-resistant Shigella Methicillin-resistant Staphylococcus aureus (MRSA) Drug-resistant Streptococcus pneumoniae Drug-resistant tuberculosis These bacteria are a serious concern and require prompt and sustained action to ensure the problem does not grow. 58
MULTIDRUG-RESISTANT ACINETOBACTER 7,300 MULTIDRUG-RESISTANT ACINETOBACTER INFECTIONS 500 DEATHS FROM MULTIDRUG- RESISTANT INFECTIONS THREAT LEVEL SERIOUS This bacteria is a serious concern and requires prompt and sustained action to ensure the problem does not grow. 12,000 ACINETOBACTER INFECTIONS PER YEAR AT LEAST THREE DIFFERENT CLASSES OF ANTIBIOTICS NO LONGER CURE RESISTANT ACINETOBACTER INFECTIONS Acinetobacter is a type of gram-negative bacteria that is a cause of pneumonia or bloodstream infections among critically ill patients. Many of these bacteria have become very resistant to antibiotics. RESISTANCE OF CONCERN Some Acinetobacter strains are resistant to nearly all or all antibiotics including carbapenems, often considered antibiotics of last resort. ■■ ■■ About 63% of Acinetobacter is considered multidrug-resistant, meaning at least three different classes of antibiotics no longer cure Acinetobacter infections. Approximately 2% of healthcare-associated infections reported to CDC’s National Healthcare Safety Network are caused by Acinetobacter, but the proportion is higher among critically ill patients on mechanical ventilators (about 7%). PUBLIC HEALTH THREAT An estimated 12,000 healthcare-associated Acinetobacter infections occur in the United States each year. Nearly 7,000 (or 63%) of these are multidrugresistant, and about 500 deaths are attributed to these infections. Multidrug-resistant Acinetobacter Percentage of all Acinetobacter healthcare-associated infections that are multidrug-resistant For more information about data methods and references, please see technical appendix. Estimated number of infections Estimated number of deaths attributed 63% 7,300 500
Page 1:
ANTIBIOTIC RESISTANCE THREATS in th
Page 4 and 5:
ACINETOBACTER 4
Page 6 and 7: ANTIBIOTIC RESISTANCE THREATS IN TH
Page 8: the risk of antibiotic-resistant in
Page 11 and 12: THE THREAT OF ANTIBIOTIC RESISTANCE
Page 13 and 14: NATIONAL SUMMARY DATA Estimated min
Page 15 and 16: Minimum Estimates of Morbidity and
Page 17 and 18: Antibiotic- Resistant Microorganism
Page 19 and 20: ■■ For several pathogens, compl
Page 21 and 22: In general, threats assigned to the
Page 23 and 24: Drug Class Important Characteristic
Page 25 and 26: Antibiotic Safety ANTIBIOTICS ARE R
Page 27 and 28: GAPS IN KNOWLEDGE OF ANTIBIOTIC RES
Page 30 and 31: CANDIDA 30
Page 32 and 33: 1. PREVENTING INFECTIONS, PREVENTIN
Page 34 and 35: CDC’s Work to Prevent Antibiotic
Page 36 and 37: Preventing Infections: CDC’s Work
Page 38 and 39: ■■ ■■ ■■ Strengthening
Page 40 and 41: Tracking Networks Data Collected Re
Page 42 and 43: Antibiotic Prescriptions per 1000 P
Page 44 and 45: 4. DEVELOPING NEW ANTIBIOTICS AND D
Page 46: Drug Name Year Approved Key Targete
Page 49 and 50: CURRENT ANTIBIOTIC RESISTANCE THREA
Page 51 and 52: CLOSTRIDIUM DIFFICILE 250,000 INFEC
Page 53 and 54: CARBAPENEM-RESISTANT ENTEROBACTERIA
Page 55 and 56: DRUG-RESISTANT NEISSERIA GONORRHOEA
Page 60 and 61: MULTIDRUG-RESISTANT ACINETOBACTER F
Page 62 and 63: DRUG-RESISTANT CAMPYLOBACTER FIGHTI
Page 64 and 65: FLUCONAZOLE-RESISTANT CANDIDA FIGHT
Page 66 and 67: EXTENDED SPECTRUM β-LACTAMASE (ESB
Page 68 and 69: VANCOMYCIN-RESISTANT ENTEROCOCCUS (
Page 70 and 71: MULTIDRUG-RESISTANT PSEUDOMONAS AER
Page 72 and 73: DRUG-RESISTANT NON-TYPHOIDAL SALMON
Page 74 and 75: DRUG-RESISTANT SALMONELLA SEROTYPE
Page 76 and 77: DRUG-RESISTANT SHIGELLA FIGHTING TH
Page 78 and 79: METHICILLIN-RESISTANT STAPHYLOCOCCU
Page 80 and 81: DRUG-RESISTANT STREPTOCOCCUS PNEUMO
Page 82: DRUG-RESISTANT TUBERCULOSIS FIGHTIN
Page 85 and 86: VANCOMYCIN-RESISTANT STAPHYLOCOCCUS
Page 87 and 88: ERYTHROMYCIN-RESISTANT GROUP A STRE
Page 89 and 90: CLINDAMYCIN-RESISTANT GROUP B STREP
Page 92 and 93: 92 EXTENDED SPECTRUM β-LACTAMASE P
Page 94 and 95: Technical Appendix Clostridium diff
Page 96 and 97: The number of deaths attributable t
Page 98 and 99: Technical Appendix Drug-Resistant C
Page 100 and 101: Technical Appendix Drug-Resistant S
Page 102 and 103: Technical Appendix Methicillin-Resi
Page 104 and 105: Technical Appendix Drug-Resistant S
Page 106 and 107: Technical Appendix Clindamycin-Resi
Page 108 and 109:
Bacteria: Single-celled organisms t
Page 110 and 111:
in people allergic to penicillin, b
Page 112 and 113:
ACKNOWLEDGEMENTS Many people in the
Page 114:
CS239559-B
show all

Antibiotic Resistance Threats in the United States, 2013 report

Create successful ePaper yourself

Delete template?

Save as template?